[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-and-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-and-obesity":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,94,0,25,[9,48,74,97,130,151,181,203,230,254,281,309,335,358,385,405,428,456,484,506,528,550,578,605,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100589990","cooking-skills-to-improve-long-term-weight-loss-in-young-adults-with-intellectual-disabilities-100589990",false,"NCT06961591","Cooking Skills to Improve Long-Term Weight Loss in Young Adults With Intellectual Disabilities","CHEF-ID","Inclusion Criteria:\n\n1. Diagnosis of mild-to-moderate intellectual disability (ID).\n2. 18-35 years of age.\n3. BMI \\>24.9, Body weight \\\u003C350lbs.\n4. Sufficient functional ability to understand directions, communicate preferences, e.g., foods, wants, and can communicate through spoken language e.g., request more to eat\u002Fdrink, asks for assistance with food preparation.\n5. Living at home with a parent\u002Fguardian, or in a supported living environment with a caregiver who assists with food shopping, meal planning, and meal preparation and agrees to serve as a study partner.\n6. Plan to attend all study required visits over the next 24 mos.\n\nExclusion Criteria:\n\n1. Unable to participate in PA.\n2. Insulin dependent diabetes as this condition requires medical monitoring beyond the scope of this study.\n3. Participation in a weight management program involving diet, PA, or pharmacotherapy in the past 6 mos.\n4. Diagnosis of Prader-Willi Syndrome.\n5. Pregnancy during the previous 6 mos., currently lactating or planned pregnancy in the following 24 mos. Participants who become pregnant will be removed from the study and referred to appropriate agencies for consultation.\n6. Serious medical risk, e.g., cancer, recent heart attack, stroke, angioplasty as determined by the PCP.\n7. Unwilling to be randomized.\n8. Unable to participate in small group, in-person instruction.\n9. Use of wheelchair or power chair as primary locomotion.","ALL","18 Years","35 Years",{"count":21,"type":22},114,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to see if adding hands-on cooking classes to a weight management program (called Chef-ID) helps young adults with intellectual disabilities lose more weight and keep it off compared to a standard weight loss program. The study will last 24 months and include three phases: 6 months of active support, 12 months of maintenance, and 6 months with no contact.\n\nThe investigators will look at how much weight participants lose over the first 18 months. Changes in cooking skills, body fat, health markers (like blood pressure and cholesterol), daily living skills, and caregiver stress will be tracked. Finally, factors that might help or prevent weight loss, and how changes in weight and body fat are linked to overall health will be explored.\n\nThis research will help inform on how to better support healthy lifestyles for people with intellectual disabilities.",[28,29],"Intellectual Disability","Overweight and Obesity",[31,32,33,34],"Weight Loss Maintenance","Cooking Skills","Weight loss","Down syndrome","RECRUITING","2026-08-10",{"date":38,"type":39},"2026-08-11","ACTUAL",{"date":41,"type":39},"2025-05-19",{"date":43,"type":22},"2029-07-01",{"name":45,"class":46},"University of Kansas Medical Center","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100645991","cardiometabolic-effects-of-the-recommended-daily-pecan-intake-dose-100645991","NCT07696403","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose: A 12-Week Randomized Controlled Trial","Inclusion Criteria:\n\n* 25-75 year-old men and women at increased risk for cardiovascular disease. Increased risk for cardiovascular disease will be defined by either elevated cholesterol profiles -or- overweight\u002Fobesity.\n* Elevated cholesterol profiles will be defined as:\n* \"Borderline High\" and\u002For \"at risk\" in two or more of the following variables (total cholesterol: 180-239 mg\u002FdL, LDL cholesterol 110-159 mg\u002FdL, triglycerides 130-199 mg\u002FdL) --or-- \"High\" in total cholesterol (240 mg\u002FdL and higher), LDL (160 mg\u002FdL or higher), or triglycerides (between 200-350 mg\u002FdL).\n* Overweight\u002Fobesity will be defined by body mass index (overweight \\> 28 kg\u002Fm2 or obesity 30 kg\u002Fm2 or greater).\n\nExclusion Criteria:\n\n* Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg\u002FdL or LDL levels greater than 190 mg\u002FdL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative.\n* Women on hormone replacement therapy less than 2 years.\n* Women who are pregnant or nursing\n* Individuals who regularly exercise more than 3h\u002Fw\n* Weight gain or loss of more than 5% body weight in the past 3 months\n* Plans to begin a weight loss\u002Fexercise regimen during the trial\n* History of medical or surgical events that could affect digestion or swallowing\n* Gastrointestinal surgeries, conditions, or disorders\n* Any chronic diseases (including moderate to severe asthma, chronic lung disease, and kidney disease)\n* Metabolic disease\n* Atherosclerosis\n* Previous MI or stroke\n* Cancer\n* Fasting blood glucose levels greater than 126 mg\u002FdL\n* Blood pressure greater than 180\u002F120 mmHg\n* Medication use affecting digestion, absorption, or metabolism (e.g. thyroid meds), lipid-lowering medications, medications for diabetes, steroid\u002Fhormone therapies, or current antibiotic cycles\n* Medically prescribed or special diets\n* Food allergies (specific to the foods in the study, including tree nuts, dairy, gluten, palm oil, and coconut oil)\n* Fish oil supplements\n* Individuals who regularly consume nuts and\u002For nut butter (defined as consumption of \\>2 servings (\\~56g) of tree nuts, nuts, or nut butter (e.g., peanut butter, almond butter) per week\n* Excessive alcohol use (greater than 3 drinks\u002Fday for men; greater than 2 drinks\u002Fday for women)\n* Tobacco or nicotine use\n* Underweight BMI (\\\u003C18.5 kg\u002Fm²)\n* Individuals who have donated blood or plasma in the past 2 weeks\n* Anemia or hemoglobin levels \\\u003C13.0 g\u002FdL (men) or \\\u003C12.5 (women)",true,"25 Years","75 Years",{"count":59,"type":22},90,[25],"Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. This study aims to examine the impact of a low dose of pecans on changes in fasting and postprandial lipid metabolism\u002Fblood lipids and markers of chronic disease risk.\n\nThe specific aims of this study are to:\n\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on fasting and postprandial blood lipids.\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on other markers of chronic disease risk.\n\nParticipants will be asked to:\n\n* Consume pecans daily for 12 weeks or maintain their current habitual diet.\n* Attend two short visits at 4 and 8 weeks for fasting blood draws, body measurements, and to collect their next 4 weeks' supply of study materials.\n* Attend two longer (5 h) testing visits, which include eating a standard breakfast meal and having their blood drawn periodically before and after breakfast.\n\nResearchers will compare the Pecan and Control groups to examine the physiologic effects of incorporating a low dose of pecans into one's diet.",[63,64,29],"Nutrition, Healthy","Dyslipidemia","NOT_YET_RECRUITING","2026-08-06",{"date":38,"type":39},{"date":69,"type":22},"2027-03",{"date":71,"type":22},"2030-02",{"name":73,"class":46},"University of Georgia",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":47},"100638870","phase-3-a-study-of-da-302168s-in-participants-with-overweightobesity-100638870","NCT07629544","A Study of DA-302168S in Participants With Overweight\u002FObesity","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight\u002FObese Participants","PANDA-1","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), both males and females;\n2. BMI requirements at screening: for obese participants, BMI ≥28 kg\u002Fm² with or without comorbidities; or for overweight participants, BMI ≥24.0 kg\u002Fm² and \\\u003C28 kg\u002Fm² with at least one of the following comorbidities: hypertension, prediabetes, dyslipidemia, weight-bearing joint pain (as determined by the investigator, excluding joint pain caused by other diseases), obstructive sleep apnea syndrome, or metabolic dysfunction-associated steatotic liver disease;\n3. Body weight change \\\u003C5% (based on participant self-report, calculated as \\[maximum weight - minimum weight\\] \u002F maximum weight, with the result rounded to one significant digit) during the 3 months prior to screening, while on diet and exercise control (based on participant self-report).\n\nExclusion Criteria:\n\n1. Type 1 diabetes, type 2 diabetes, or other specific types of diabetes (excluding gestational diabetes);\n2. Secondary obesity, history of bariatric surgery;\n3. Presence of gastrointestinal diseases affecting drug absorption, dysphagia;\n4. Personal\u002Ffamily history of medullary thyroid carcinoma, C-cell hyperplasia, or multiple endocrine neoplasia type 2; uncontrolled hyperthyroidism or hypothyroidism without standard stable management; thyroid nodule with TI-RADS grade 4 or above;\n5. History of acute pancreatitis, chronic pancreatitis, or pancreatic injury within 6 months prior to screening (high-risk pancreatic conditions); acute cholecystitis within the past 3 months, or current cholecystitis, cholangitis, cholelithiasis, or other high-risk gallbladder diseases (except for those with prior cholecystectomy and judged eligible by the investigator);\n6. Severe unstable psychiatric disorder, depression, or history of suicide attempt; score ≥15 on the Patient Health Questionnaire-9 (PHQ-9) at screening, or presence of suicidal ideation\u002Fsuicidal behavior indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS);\n7. Any of the following abnormal clinical laboratory results (local laboratory) at screening: anemia (hemoglobin \\\u003C110 g\u002FL for males, \\\u003C100 g\u002FL for females); liver enzymes, bilirubin, amylase, or lipase exceeding the specified multiples of the upper limit of normal; calcitonin ≥50 ng\u002FL (pg\u002FmL); estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²; triglycerides \\>5.65 mmol\u002FL; thyroid-stimulating hormone \\>6 mIU\u002FL or \\\u003C0.4 mIU\u002FL;\n8. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n9. Abnormal heart rate on resting electrocardiogram, atrioventricular block, prolonged QTcF interval, bundle branch block, or other clinically significant arrhythmias; history of myocardial infarction, unstable angina, severe cardiac insufficiency, coronary intervention\u002Fbypass, or other cardiovascular\u002Fcerebrovascular diseases within 6 months prior to enrollment;\n10. Use of weight-loss drugs or weight-loss herbal medicines, any hypoglycemic agents, antidepressants, antipsychotics, antiepileptics, or lithium salts within 3 months prior to screening; use of systemic glucocorticoids (except for continuous cumulative use \\\u003C7 days); active autoimmune disease requiring systemic glucocorticoid therapy during the study period.",{"count":83,"type":22},840,[85],"PHASE3","This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.",[29],"2026-08-04",{"date":66,"type":39},{"date":91,"type":39},"2026-06-19",{"date":93,"type":22},"2027-10-19",{"name":95,"class":96},"Chendu DIAO Pharmaceutical Group CO., LTD.","INDUSTRY",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100529981","effect-of-sleep-extension-on-ceramides-in-people-with-overweight-and-obesity-100529981","NCT06180837","Effect of Sleep Extension on Ceramides in People With Overweight and Obesity","Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 27.5-34.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)\n3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg\u002FdL or HbA1c ≥6.5%\n4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.\n5. Cancer that has been in remission less than 5 years\n6. Pregnant\u002Fnursing, experiencing menopause or post-menopausal\n7. Shift-work: current or history of within last year\n8. Weight change: \\>10% of body weight over prior six months\n9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n10. Currently smoking\n11. Alcohol intake\\>14 drinks per week or \\>3 drinks per day","45 Years",{"count":106,"type":22},70,[25],"The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[110,29,111,112,113,114,115,116,117],"Lifestyle Factors","Insulin Sensitivity","Eating Habit","Sleep Hygiene","Type 2 Diabetes","Sleep","Sleep Deprivation","Insufficient Sleep Syndrome",[119,120],"sleep","insulin sensitivity","2026-08-03",{"date":123,"type":39},"2026-08-05",{"date":125,"type":39},"2024-02-12",{"date":127,"type":22},"2028-05",{"name":129,"class":46},"University of Utah",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":47},"100511760","circadian-intervention-to-improve-cardiometabolic-health-100511760","NCT05943626","Circadian Intervention to Improve Cardiometabolic Health","Timing of Circadian Synchronizers: The TOCS Study","TOCS","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 25.0-34.9 kg\u002Fm2,\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., diagnosed diabetes, cardiovascular disease, or kidney disease)\n3. Use of prescription drugs or substances known to influence sleep or glucose metabolism\n4. Shift-work: current or history of within last year\n5. Weight change: \\>10% of body weight over prior six months\n6. Experiencing menopause or post-menopausal\n7. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n8. Currently pregnant or planning to become pregnant, or currently lactating.\n9. Currently smoking\n10. Alcohol intake \\>3 drinks per day or \\>14 drinks per week",{"count":139,"type":22},20,[25],"The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[143,114,115,144,110,29,111,112,113],"Cardiometabolic Syndrome","Time Restricted Feeding",{"date":123,"type":39},{"date":147,"type":39},"2023-06-13",{"date":149,"type":22},"2027-06",{"name":129,"class":46},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":158,"maxAge":57,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":47},"100650527","cognitive-effects-of-hesperidin-in-overweightobese-older-adults-100650527","NCT07750223","Cognitive Effects of Hesperidin in Overweight\u002FObese Older Adults","A Randomized Controlled Trial of Hesperidin for Improving Cognitive Function in Overweight and Obese Middle-Aged and Older Adults","Inclusion Criteria:\n\n* Age 55-75 years\n* BMI ≥ 24 kg\u002Fm² or waist circumference ≥ 90 cm (men) \u002F ≥ 85 cm (women)\n* Willing to participate and sign informed consent\n\nExclusion Criteria:\n\n* MMSE score \\\u003C 20\n* History of neurological diseases (Parkinson's, Alzheimer's, stroke, etc.)\n* Malignant tumors, severe liver\u002Fkidney\u002Fgastrointestinal diseases\n* Use of weight-loss drugs or antidepressants (except statins) within recent months\n* Strict vegetarians, binge eating disorder, heavy alcohol consumption\n* Participation in other intervention studies\n* Other conditions judged by investigators as unsuitable","55 Years",{"count":160,"type":22},105,[25],"A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults.\n\nA total of 105 participants, aged 55-75 years with a BMI ≥24 kg\u002Fm² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg\u002Fday), or high-dose hesperidin (600 mg\u002Fday).\n\nThe primary aim is to see if hesperidin supplementation enhances cognitive performance - specifically executive function, memory, and attention - and to explore any dose-response relationship.\n\nSecondary aims include examining changes in gut microbiota composition and related metabolites, as well as exploring potential mechanisms behind any observed effects.\n\nThe findings are expected to provide scientific evidence on whether hesperidin could serve as a nutritional strategy to support cognitive health in this population.",[164,29],"Cognitive Dysfunction",[166,167,168,169,170,171,172],"Hesperidin","Cognitive Function","Citrus Flavonoids","Gut Microbiota","Nutritional Intervention","Middle-aged and Elderly","Randomized Controlled Trial","2026-08-01",{"date":66,"type":39},{"date":176,"type":39},"2026-02-01",{"date":178,"type":22},"2027-03-30",{"name":180,"class":46},"Min Hou",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":188,"maxAge":18,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":47},"100635934","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-hrs9531-injection-in-adolescents-with-obesity-100635934","NCT07559136","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity","A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of HRS9531 Injection in Chinese Adolescents With Obesity","Inclusion Criteria:\n\n1. Male or female subjects who are aged ≥12 years and \\\u003C18 years at the time of signing the informed consent;\n2. At screening, the BMI meets the obesity criteria according to \"WS\u002FT586-2018 Screening Criteria for Overweight and Obesity in School-age Children and Adolescents\";\n3. Subjects who have maintained a controlled diet and exercise for at least 12 weeks prior to screening, with no more than a 5% decrease in BMI (as reported by the subject, parent, or legal guardian);\n\nExclusion Criteria:\n\n1. Presence of clinically significant lab results at screening visit;\n2. Uncontrollable hypertension;\n3. Medical history or illness that affects your weight;\n4. History of diabetes;\n5. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening;\n6. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;\n7. Use of drugs or treatments that may have caused significant weight gain or loss within the 3 months prior to screening;\n8. Pre-adolescent participants (Tanner phase I);\n9. Patients with blood donation or blood loss ≥400 mL or receiving blood transfusion within 3 months before screening.\n10. Surgery is planned during the tria;\n11. Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process；\n12. In the investigator's judgment, there are circumstances that affect subject safety or any other conditions that interfere with the evaluation of the test results.","12 Years",{"count":190,"type":22},48,[192],"PHASE1","The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity",[29],"2026-07-30",{"date":197,"type":39},"2026-07-31",{"date":199,"type":39},"2026-06-12",{"date":69,"type":22},{"name":202,"class":96},"Fujian Shengdi Pharmaceutical Co., Ltd.",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":47},"100648684","phase-1-a-phase-1-double-blind-randomized-study-to-evaluate-the-safety-tolerability-pharmacodynamics-and-pharmacokinetics-of-single-dose-and-multiple-doses-of-cg-0416-in-healthy-participants-100648684","NCT07724431","A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.","Inclusion Criteria:\n\n1. Male and female participants aged 18 to 60 years, inclusive, at the time of screening.\n2. BMI of ≥ 18 kg\u002Fm2 to ≤ 32 kg\u002Fm2 for SAD and ≥ 21 kg\u002Fm2 to ≤ 35 kg\u002Fm2 for MAD at screening, and body weight \\> 50 kg for SAD and MAD.\n3. Participants will be assessed to be in good health by the investigator, such as no clinically relevant abnormalities that will affect participant safety in the opinion of the investigator based on medical history, physical examination, clinical laboratory assessments (hematology, serum chemistry, coagulation, urinalysis, TH), and 12-lead ECG.\n4. LDL-C \\> 1.8 mmol\u002FL (70 mg\u002FdL) in SAD, LDL-C \\> 2.6 mmol\u002FL (100 mg\u002FdL) in MAD.\n5. Self-reported stable weight (within ± 5% change) for at least 3 months prior to screening.\n6. Participant and his\u002Fher sexual partner are not planning to fall pregnant and male participants can't donate sperm for 95 days after the last dose of study drug and willing to use two or more effective contraception methods (contraception guidance is provided in Appendix 17.1). Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug and must not be breastfeeding, lactating or planning pregnancy during the study period. WOCBP are defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral salpingectomy or bilateral oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in the absence of other biological causes. In addition, females under the age of 55 years must have a documented serum FSH level \\> 40 mIU\u002FmL to confirm menopause. Male participants with potentially postmenopausal partners who are under the age of 55 years must use condoms unless their partner's postmenopausal status has been confirmed by FSH level.\n7. Participants have a full understanding of the trial content, process and possible adverse reactions, and voluntarily signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Clinically significant infection and\u002For cardiovascular, hematologic, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunologic, dermatologic, neurologic, current or history of ADHD, anxiety or depression, or psychiatric disease at screening that, or its treatment, may have interfered with the conduct of the study (e.g., study procedure compliance, safety assessment, study results interpretation) or, in the judgment of the investigator, will have placed the participant at an unacceptable risk if participating in the study.\n2. Clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immunological, psychiatric or cardiovascular disease) within 6 months before screening.\n3. Thyroid diseases: a) active hyperthyroidism; b) TSH \\>7 IU\u002FL with symptoms of hypothyroidism or \\>10 IU\u002FL without symptoms.\n4. Diagnosis of type 1 or 2 diabetes or other autoimmune diabetes (fully resolved gestational diabetes will be permitted).\n5. Glycated hemoglobin (HbA1c) \\> 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL.\n6. Fasting (TG ≥ 500 mg\u002FdL (or 5.65 mmol\u002FL) at screening.\n7. Participant meets any of the following:\n\n   1. Transaminases (AST, ALT) \\> 1.5 × ULN.\n   2. Alkaline phosphatase (ALP) \\> 1.5 × ULN.\n   3. Serum total bilirubin \\> 1.5 × ULN (participants diagnosed with Gilbert's syndrome at screening are allowed to meet all other criteria).\n   4. Platelet count \\\u003C 100,000\u002Fmm³.\n   5. International normalized ratio (INR) \\> ULN (as per the local laboratory reference range).\n   6. Albumin \\\u003C 35 g\u002FL.\n   7. Estimated glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73m2 per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 formula.\n8. Severe allergic diseases or suspected allergy to any component of the study drug, allergic constitution (multiple drug and food allergy) judged by the investigator.\n9. Any of the following abnormalities on the 12-lead ECG at screening:\n\n   1. QTcF (Fridericia-corrected QT interval) \\> 450 msec for males or \\> 470 msec for females.\n   2. In addition to the above, any clinically significant ECG abnormality, as judged by the investigator.\n10. Systolic blood pressure \\> 145 mmHg and diastolic blood pressure \\> 95 mmHg in supine position (at least 5 minutes) at screening, confirmed by retest.\n11. Use of antibiotics or immunosuppressive drugs (e.g., systemic corticosteroids) within 30 days prior to administration of CG-0416 on Day 1.\n12. Any short-term or long-term treatment for obesity within 3 months prior to screening.\n13. For use of prescription medication, within 14 days or 5 half-lives (whichever is longer) before screening with the exception of hormone replacement and contraception therapy. For use of over-the-counter (OTC) medications, food supplements (excluding routing vitamins, paracetamol, ibuprofen), weight loss and fat reduction supplements (L-carnitine, green coffee extract, chitosan, weight loss tea, yerba mate tea, meal replacement, etc.), supplements for thyroid endocrine disruption (iodine supplements, seaweed and kelp extracts, etc.), lipid-lowering supplements (fish oil, etc.) etc. 7 days before screening is sufficient (Only vitamins and other supplements that do not affect the study drug are allowed to be used. Other supplements are not permitted).\n14. Smoking \\> 5 cigarettes (or equivalent amount of nicotine products) per week within 30 days before the screening or inability to abstain from tobacco products during the study.\n15. Any vaccination within 14 days prior to screening or anticipated administration of a live vaccine during the study.\n16. Receipt of an investigational drug or device or participation in a drug study within 60 days (or 5 half-lives of the drug, whichever is longer) before dosing on Day 1.\n17. Positive during screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (amplification test to confirm if positive; cured hepatitis C can be enrolled), or human immunodeficiency virus (HIV) antibody, treponema pallidum antibody.\n18. History of drug abuse within 6 months before screening, or positive drug abuse test at screening.\n19. Weekly alcohol consumption of more than 10 units of alcohol (1 unit of alcohol = 360 mL of beer or 45 mL of spirit with the alcohol content of 40% or 150 mL of wine) in any week within the past 3 months before screening; intake of alcohol-containing products within 48 hours prior to the first dose of study drug or inability to abstain from any alcohol during the study, or positive alcohol test at screening.\n20. Donation of more than 400 mL of blood or plasma within 30 days before screening or planned donation within 90 days of study treatment administration.\n21. Consumption\u002Fconsumption of coffee, tea, grapefruit, chocolate or soft drinks such as cola containing methylxanthines (theophylline, caffeine or theobromine) within 48 hours before dosing.\n22. Strenuous exercise, such as weightlifting, sprinting, long-distance running, cycling, swimming, and playing soccer, is performed within 72 hours before screening and any study visit until the follow-up has been completed; if it is not within the window period before the above-mentioned screening and study visits, maintenance of daily exercise or activity plan is allowed.","60 Years",{"count":211,"type":22},64,[192],"A Phase 1, double-blind, randomized study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of single dose and multiple doses of CG-0416 in healthy participants. HongKong Curegene Innovation Co. Limited is developing the study drug CG-0416 as a potential new treatment for overweight and obesity. The purpose of this research is to investigate the safety, tolerability (if any side effects occur), pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body), of single and multiple oral doses of a study drug called CG-0416.",[29],[216,217,218,219,220],"weight loss","CG-0416","Curegene","Obesity","MASH","2026-07-23",{"date":223,"type":39},"2026-07-24",{"date":225,"type":22},"2026-07",{"date":227,"type":22},"2027-04",{"name":229,"class":96},"HongKong Curegene Innovation Co., Limited",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100546085","functional-improvement-in-osa-and-copd-with-a-telehealth-lifestyle-and-exercise-intervention-100546085","NCT06390345","Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention","FOCuSEd","Inclusion Criteria:\n\n* COPD: Defined by presence of airflow obstruction (FEV1\u002FFVC \\\u003C 0.70) on post-bronchodilator spirometry\n* ≥10 pack year history of tobacco use\n* Self-reported clinician diagnosis of OSA (or presence of OSA on research HSAT)\n* BMI ≥ 25 kg\u002Fm2\n* Symptoms of dyspnea defined by MMRC score of ≥1\n\nExclusion Criteria:\n\n* Self-report of weight change \\>15 lbs. during prior 3 months\n* Current active weight loss treatment, including: 1) research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS, MOVE!); 2) other weight loss or related behavioral health or wellness programs led by trained personnel (professional or lay) in the local community; 3) prescription weight loss medication within last 3 months; and scheduled bariatric surgery.\n* Severe illness from any cause\n* Diagnosis of bulimia or history of purging behavior\n* Active enrollment in pulmonary rehabilitation\n* Safety and\u002For adherence concerns due to severe physical or mental health issues or life expectancy \\\u003C 12 months. These include but may not be limited to: unstable cardiac arrhythmias, active or recent (within one month) myocardial infarction, active or recent (within one month) COPD exacerbation, angina not well-controlled with medication, significant musculoskeletal comorbidities or physical infirmities that preclude participation in an exercise program, and the need for supplemental oxygen ≥ 5 lpm at rest or with exertion.\n* Pregnant, lactating, or planning to become pregnant during the study period\n* Participation in other intervention studies.\n* Prisoner\n* Unable to complete surveys in English",{"count":238,"type":22},400,[25],"The investigators will conduct a Type I hybrid effectiveness-implementation study to test an integrated telehealth intervention among 400 overweight and obese patients with Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA). The investigators will include eligible participants receiving primary care at one of five Department of Veterans Affairs (VA) medical centers and their community-based outpatient clinics. The investigators will randomize patients in a 1:1 ratio to the multi-component intervention or \"enhanced\" usual care, stratifying by age (≥65 vs. \\\u003C 65) and site. Participants randomized to the intervention will receive an integrated, telehealth-delivered intervention composed of a self-directed lifestyle program and supervised pulmonary rehabilitation. At the end of 3 months, the investigators will offer to enter a recommendation for weight management medications on behalf of eligible intervention participants. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach. For participants randomized to the \"enhanced\" usual care group, study staff will prompt the patient's primary care provider to refer them to existing weight loss management and pulmonary rehabilitation programs. Follow-up will occur at virtual visits at 3 and 12 months. The primary effectiveness outcome at 1-year is quality of life measured by the SF-12 Physical Component Summary Score. Secondary effectiveness outcomes will include other measures of quality of life (including sleep related impairment), sleep disturbance, disease severity (COPD exacerbations and respiratory event index for OSA), depression, social support, weight loss and cardiovascular risk. In addition to assessing effectiveness, investigators will also conduct a concurrent implementation process evaluation using the RE-AIM framework.",[242,243,29],"Chronic Obstructive Pulmonary Disease","Obstructive Sleep Apnea","2026-07-20",{"date":246,"type":39},"2026-07-22",{"date":248,"type":39},"2024-07-29",{"date":250,"type":22},"2028-10-01",{"name":252,"class":46},"Seattle Institute for Biomedical and Clinical Research",5,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":17,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":47},"100537832","health-outcomes-in-c-section-infants-with-fecal-microbiota-transplantation-100537832","NCT06282952","Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation","Section-Born Infants and SUccessful Health Outcomes After Fecal Microbiota Transplantation (SISU-FMT)","SISU-FMT","Inclusion Criteria:\n\nPregnant women aged 18 to 49 years Scheduled for elective cesarean delivery at term (≥37 completed weeks of gestation) Willing and able to provide written informed consent Infant eligible for study participation following birth\n\nExclusion Criteria (Mother):\n\nAge \\\u003C18 years or \\>49 years Multiple pregnancy Regular use of immunosuppressive biological medication Diagnosed immunodeficiency in the mother Diagnosed immunodeficiency in a first-degree relative of the unborn child Known or suspected major congenital structural anomaly in the fetus Known or suspected fetal immunodeficiency Previous participation in the SISU-FMT study\n\nExclusion Criteria (Infant):\n\nPreterm birth (\\\u003C37 completed weeks of gestation) Birth weight \\\u003C2500 g Admission to a neonatal intensive care unit prior to the intervention Requirement for respiratory support prior to the intervention Requirement for systemic antibiotic treatment prior to the intervention","0 Hours","6 Hours",{"count":265,"type":22},460,[25],"This single-center randomized controlled trial evaluates whether donor-derived fecal microbiota transplantation (FMT) administered within 6 hours after birth can improve gut microbiota development and reduce the risk of immune-mediated and metabolic diseases in infants born by elective cesarean delivery. Newborns are randomized 1:1 to receive either donor-derived FMT or standard postnatal care. Participants are followed through 36 months of age with stool samples, questionnaires, growth assessments, and health data collection, with registry-based follow-up continuing until 10 years of age.",[269,270,29],"Fecal Microbiota Transplantation","Cesarean Section",[269,270,29],"2026-07-17",{"date":274,"type":39},"2026-07-21",{"date":276,"type":39},"2026-03-31",{"date":278,"type":22},"2036-12-31",{"name":280,"class":46},"Oulu University Hospital",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":55,"sex":288,"minAge":289,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":47},"100527454","an-acceptance-based-healthy-lifestyle-intervention-for-diverse-adolescents-100527454","NCT06147973","An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents","Wellness Achieved Through Changing Habits (WATCH): An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents","Inclusion Criteria:\n\n* Ages 14-19\n* Gender identification as girl\n* BMI percentile ≥ 85th percentile for sex-and-age\n\nExclusion Criteria:\n\n* Experience of weight loss of ≥5% of body weight in the past 6 months for any reason except post-partum weight loss\n* Having recently begun or changed the dosage of any medication known to affect appetite or body composition within the last 3 months\n* Plans to move out of the area within the next year\n* Active cancer or cancer requiring treatment in the past 2 years (except non-melanoma skin cancer)\n* Active or chronic infections (e.g., HIV or TB)\n* Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease in the past 6 months\n* Active kidney disease\n* History of bariatric surgery\n* Lung disease: chronic obstructive airway disease requiring use of oxygen (e.g., emphysema or chronic bronchitis)\n* Diagnosed diabetes (type 1 or 2)\n* Any condition prohibiting physical activity\n* Diagnosis of an eating disorder\n* Have a mental handicap or are currently experiencing other severe psychopathology that would limit their ability to engage in the treatment program (e.g., severe depression, active psychotic disorder)\n* Recent or ongoing problem with drug abuse, alcohol abuse, or addiction\n* Currently pregnant or less than 3 months post-partum\n* Anticipation of a possible pregnancy in the next year\n* Unwillingness to report possible or confirmed pregnancies promptly during the course of the trial","FEMALE","14 Years","19 Years",{"count":292,"type":22},148,[25],"The goal of this clinical trial is to learn about cardiovascular disease risk among adolescent girls with overweight\u002Fobesity. The main questions this trial aims to answer are:\n\n1. Does an acceptance-based healthy lifestyle intervention demonstrate more weight loss than a health education intervention?\n2. Does an acceptance-based healthy lifestyle intervention show more improvements in participants' physiological, health-related, and psychological factors compared to a health education intervention?\n\nParticipants in this trial will:\n\n1. Engage in treatment for 6-months, comprising of a mixture of in-person and remote group sessions, occurring at Drexel University or over a video-conferencing platform.\n2. Complete various assessments. These include self-reported questionnaires, measures of weight, height, body composition, blood pressure, and blood lipids, and wearing of smart watches to measure sleep and physical activity.\n\nResearchers will compare the acceptance-based and health education intervention groups to see if the acceptance-based treatment will indeed be effective in improving participants' health outcomes.",[29],[297,298,299,300],"adolescent obesity","cardiovascular disease risk","healthy lifestyle intervention","acceptance-based","2026-07-16",{"date":244,"type":39},{"date":304,"type":39},"2024-02-14",{"date":306,"type":22},"2028-01-01",{"name":308,"class":46},"Nemours Children's Clinic",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":55,"sex":17,"minAge":315,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":320,"conditions":321,"keywords":325,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":47},"100498462","phase-2-taxi-roadmap-realizing-optimization-around-diet-and-physical-activity-100498462","NCT05770570","Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)","Inclusion Criteria:\n\nFor COMIDA participants only:\n\n* Self-Identifies as Mexican American or Mexican\n* Seeking services at the VDS of the Mexican Consulate\n* Prefers to speak in Spanish\n* All adults at least 18 years of age\n* Screens as obese (an adult who has a Body Mass Index (BMI) 30 or higher) or overweight (an adult who has a BMI between 25 - 29.9)\n* Agrees to be audio recorded\n\nFor SANOS focus group participants only:\n\n* Self-identifies as Hispanic\u002FLatino;\n* Seeking services at VDS or VDS Mobile;\n* Prefers to speak in Spanish;\n* At least 18 years of age;\n* Screens as obese (BMI ≥ 30 kg\u002Fm\\^2) or overweight (BMI of 25 - 29.9 kg\u002Fm\\^2);\n* Agrees to be audio recorded\n\nFor SANOS RCT participants only:\n\n* Self-identifies as Hispanic\u002FLatino;\n* Seeking services at VDS or VDS Mobile;\n* Prefers to speak in Spanish;\n* At least 18 years of age;\n* Screens as obese (BMI ≥ 30 kg\u002Fm\\^2) or overweight (BMI of 25 - 29.9 kg\u002Fm\\^2);\n* Owns a cell phone capable of receiving text messages;\n* Agrees to be audio recorded\n\nFor Family COMIDA participants only:\n\n* Self-Identifies as Hispanic\u002FLatino\n* Seeking services at the VDS (or has used VDS services in the past) of the Mexican - Consulate or VDS Mobile\n* Prefers to speak in Spanish\n* At least 18 years of age\n* Has at least one child under age 18 living in the same household\n* Owns a cell phone capable of receiving text messages\n* Willing to receive text messages (3 texts per week for 3 months)\n* Owns an internet connected device (eg, cell phone, tablet, etc) capable of conducting teleconference calls (eg, Zoom)\n\nFor ROADmAP RCT participants only:\n\n* At least 21 years of age\n* Full-time (drives at least 35 hours per week) licensed taxi\u002FFHV driver\n* Driver for at least 6 months\n* Seeking Health Fairs (or has used Health Fairs services in the past)\n* Speaks English, French, Bengali, or Spanish\n* Screens a as obese (BMI ≥ 30 kg\u002Fm2 \\[≥25 kg\u002Fm2 for South Asians\\]) or overweight (BMI of 25 - 29.9 kg\u002Fm2 s \\[23- 24.9 kg\u002Fm2 for South Asians\\])\n\n  * (BMI cut-offs are lower for South Asians, per WHO and American Diabetes Association recommendations)\n* Owns a cell phone capable of receiving text messages\n* Agrees to be audio-recorded\n\nFor ROADmAP Phase 2 participants only:\n\n* At least 21 years of age\n* Driver who participated in ROADmAP RCT or manager at a taxi garage, Uber, Lyft or driver serving\u002Funion\u002Forganization\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nFor COMIDA participants only:\n\n* Will not be in the NYC area for the study duration (3-4 months) Is pregnant or might be pregnant\n* Lactating women\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)\n* Has dietary restrictions (i.e. liquid diet)\n* Does not have a phone that accepts text messages or unwilling to accept text messages\n* Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional\"s judgment\n* Has another family member already enrolled in COMIDA (as determined by patient report)\n\nFor SANOS focus group participants only:\n\n* Is pregnant or might be pregnant; lactating women;\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate);\n* Has dietary restrictions (i.e. liquid diet);\n* Has a household member who has already participated (or agreed to participate);\n\nFor SANOS RCT participants only:\n\n* Is pregnant or might be pregnant; lactating women; for the study duration (6 months)\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate); restricting diet;\n* Currently has dietary restrictions (i.e. liquid diet);\n* Has a household member who has already participated (or agreed to participate);\n* Has already participated in the study\n* Will not be in the NY Metropolitan area for the study duration (6 months) Works for or with the Mexican consulate (including employment and\u002For collaborative or volunteer services)\n\nFor Family COMIDA participants only:\n\n* Is pregnant or might be pregnant; lactating women for the study duration (3 months)\n* Will not be in the NY Metropolitan area for the study duration (3 months) Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)\n* Has dietary restrictions (i.e. liquid diet)\n* Has another family member who has already participated in COMIDA or SANOS\n* Has already participated in the study\n* Works for or with the Mexican consulate (including employment and\u002For collaborative or volunteer services)\n\nFor ROADmAP RCT participants only:\n\n* Is pregnant or might be pregnant; lactating women; for the study duration (12 months)\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate) that may restrict diet\n* Currently has dietary restrictions (i.e. liquid diet)\n* Has a household member who has already participated (or agreed to participate)\n* Has already participated in the study\n* Will not be in the NY Metropolitan area for 6 months from study enrollment\n* Is currently taking Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity Saxenda, Victoza, Phentermine (Adipex, Lomaira), Extended-release Phentermine\u002FTopiramate (Qsymia), Extended-release Naltrexone\u002FBupropion (Contrave), Plenity, Orlistat (Xenical) or Other GLP-1 receptor agonist, or any other drug to treat obesity or there is less than 7 weeks since last dosage.\n* Has undergone weight loss\u002Fbariatric surgery or is planning to undergo such surgery in the next 12 months.","21 Years",{"count":317,"type":22},1817,[319],"PHASE2","The researchers will conduct 'Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity)', which also utilizes MOST, and the same 4 obesity intervention components as in SANOS, but targets the overweight\u002Fobesity crisis in another at-risk, low socioeconomic status (SES) population, taxi and for-hire vehicle (FHV) drivers (Lyft, Uber, etc.). ROADMAP also utilizes an effectiveness- implementation hybrid type 1 design. Hybrid trials, which blend effectiveness and implementation studies, can lead to more rapid translational uptake and more effective implementation. Taxi and FHV drivers are a growing, multilingual, hard-to-reach, predominantly immigrant and minority essential worker population. There are over 750,000 licensed taxi and FHV drivers in in the U.S. and over 185,000 in New York City (NYC). They have higher rates of overweight\u002Fobese range body mass index (BMI) than New Yorkers in general (77% vs 56%) and have high rates of elevated waist circumference, sedentary behavior, poor diets, and health care services underutilization. ROADmAP will test 4 evidence- and theory-based (Social Cognitive Theory \\[SCT\\]) behavior change intervention components. We will use MOST to identify which of the 4 components contribute most significantly and cost-effectively to weight loss among NYC drivers recruited at workplace health fairs (HFs) and virtually. Objectives are to apply MOST to design an optimized version of a scalable, lifestyle intervention for taxi\u002FFHV drivers, and then to conduct a mixed methods multistakeholder process evaluation to facilitate widespread intervention implementation.",[322,29,323,219,324],"Overweight","Overweight or Obesity","Obese",[326,322,29,323,219,324,327],"Focus Groups","Memorial Sloan Kettering Cancer Center","2026-07-15",{"date":272,"type":39},{"date":331,"type":39},"2022-12-22",{"date":333,"type":22},"2027-08-11",{"name":327,"class":46},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":47},"100491618","metabolic-and-inflammatory-outcomes-of-the-ketogenic-diet-comparing-saturated-and-unsaturated-fat-sources-100491618","NCT05681468","Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources","KETO-IM","Inclusion Criteria:\n\n* Having overweight or obesity and HbA1C ≥ 5.7% at screening\n\nExclusion Criteria:\n\n* Individuals with specific nutritional habits preventing them from adhering to nutritional recommendations\n* Pregnant women\n* People on dialysis or recommended to follow a low-protein diet (base on glomerular filtration rate)\n* Familial hypercholesterolemia or hypertriglyceridemia\n* Transitioning trans-gender\n* For safety purposes, other individuals would be excluded if are under unstable health conditions.","70 Years",{"count":344,"type":22},175,[25],"The goal of this clinical trial is to compare a healthy KETO diet supplemented with canola oil (KETO-Can) compared to a traditional KETO diet high in saturated fat (KETO-Sat) and low-fat diet (LFD) in adults at high risk of or diagnosed with type 2 diabetes. The main question\\[s\\] it aims to answer are:\n\n* Effects on CVD risk factors (plasma cholesterol, TG, ApoB100, glucose, insulin and HbA1C).\n* Effects on systemic inflammation and immune function.\n* Adherence to interventions.\n\nParticipants will be randomized into 1 of the dietary treatments during which they will follow a Keto or a low-fat diet.\n\nComparisons among groups at 3 and 6 months of intervention will be conducted.",[348,349,29],"PreDiabetes","Diabetes Mellitus, Type 2","2026-07-14",{"date":301,"type":39},{"date":353,"type":39},"2023-09-18",{"date":355,"type":22},"2027-01-31",{"name":357,"class":46},"University of Alberta",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":288,"minAge":18,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":47},"100553857","time-restricted-eating-for-postpartum-weight-loss-100553857","NCT06491537","Time-restricted Eating for Postpartum Weight Loss","Use of Early Time-restricted Eating to Promote Weight Loss and Improve Cardiometabolic Health in Postpartum Women","Time4Mom","Inclusion Criteria:\n\n* 18 years of age or older\n* Experienced a healthy singleton pregnancy\n* 6-16 weeks postpartum at enrollment\n* Body mass index ≥25 at enrollment\n* Willing to consent\n\nExclusion Criteria:\n\n* Self-reported major health condition (such as renal disease, cancer, or Type 1 or Type 2 diabetes)\n* Current treatment for severe psychiatric disorder (such as schizophrenia)\n* Self-reported diagnosis of anorexia or bulimia\n* Current use of medication expected to significantly impact body weight\n* Current substance abuse\n* Participation in another dietary and\u002For weight management intervention postpartum\n* Performing overnight shiftwork \\>1x\u002Fweek\n* Regularly fasting ≥14 hr\u002Fday or completing twelve or more 24-hr fasts within the past year\n* Unable to understand and communicate in English",{"count":367,"type":22},60,[25],"This study is being done to assess the feasibility and acceptability of a time-restricted eating intervention among postpartum women with overweight\u002Fobesity.",[371,29],"Postpartum Weight Retention",[373,374,375],"postpartum","weight management","time-restricted eating","2026-06-24",{"date":378,"type":39},"2026-06-29",{"date":380,"type":39},"2025-05-22",{"date":382,"type":22},"2029-02-01",{"name":384,"class":46},"University of Alabama at Birmingham",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":391,"targetDuration":4,"studyType":393,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":47},"100487846","breathing--blood-pressure-100487846","NCT05632406","Breathing & Blood Pressure","Inclusion Criteria:\n\n• Body mass index values of ≤40 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Not weight stable (\\\u003C5% change in body mass over the past six months)\n* Overt cardiovascular, neurological, renal, liver, and\u002For metabolic illness (e.g., diabetes mellitus)\n* Current, or history of uncontrolled, Stage 2 hypertension (blood pressure \\>140 \u002F 90 mmHg; anti-hypertensive medications are permitted)\n* Diagnosed obstructive sleep apnea\n* Previous bariatric surgery\n* Diagnosis or signs (e.g., values below the lower limit of normal) of overt airway disease(s)\n* Current or recent (regular use within the past 6 months) use of tobacco or nicotine products (e.g., cigarettes, vaping)\n* Per the POWERbreathe® company:\n* Patients who have undergone recent abdominal surgery and those with abdominal hernia.\n* Asthma patients who have a very low symptom perception and suffer from frequent, severe exacerbations or with an abnormally low perception of dyspnoea.\n* If a patient is suffering from a ruptured eardrum or any other condition of the ear.\n* Patients with marked elevated left ventricular end-diastolic volume and pressure.\n* Patients with worsening heart failure signs and symptoms after a respiratory\u002Finspiratory muscle training (IMT) session\n* If you are suffering from a cold, sinusitis, or respiratory tract infection, we advise that you do not use your POWERbreathe IMT device.\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant (self-reported and urine pregnancy test conducted), lactating (self-reported), or post-menopausal (self-reported) females\n* Prisoners",{"count":392,"type":22},80,"OBSERVATIONAL","The purpose of this study is to determine the effect of obesity on cardiovascular responses during various breathing maneuvers.",[396,29],"Healthy",{"date":398,"type":39},"2026-06-26",{"date":400,"type":39},"2023-10-25",{"date":402,"type":22},"2027-06-30",{"name":404,"class":46},"Florida State University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":288,"minAge":18,"maxAge":104,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":253},"100448849","intensive-glycemic-targets-in-overweight-and-obese-women-with-gestational-diabetes-100448849","NCT05124808","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes","Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes Mellitus: A Multicenter Randomized Trial","iGDM","Inclusion Criteria:\n\n* Pregnant women between the ages of 18-45\n* Singleton gestation\n* Gestational age between 12 0\u002F7-32 6\u002F7 weeks' gestation with gestational diabetes diagnosed during this time frame using either a 50g 1-hr GCT ≥200 mg\u002FdL or two or more abnormal values on a 100g OGTT using the Carpenter-Coustan Criteria\n* Overweight or obese BMI at the first prenatal visit (BMI ≥25 kg\u002Fm2 or ≥23 kg\u002Fm2 in Asian Americans)\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with members of the study team, despite the presence of an interpreter\n* Planned delivery at a non-study affiliated hospital\n* Known renal disease with a baseline creatinine \\>1.5 mg\u002FdL\n* Significant fetal anomalies diagnosed prior to study enrollment (these will include anomalies such as gastroschisis, spina bifida, complex congenital heart disease, or serious karyotypic anomalies that may lead to early delivery or increased risk of neonatal death)\n* Oral or IV\u002FIM steroid use within 7 days of study enrollment",{"count":414,"type":22},828,[25],"This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.",[418,419,29],"Gestational Diabetes","Pregnancy, High Risk","2026-06-22",{"date":376,"type":39},{"date":423,"type":39},"2022-03-01",{"date":425,"type":22},"2026-12-31",{"name":427,"class":46},"Indiana University",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":393,"phases":4,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":47},"100641777","validity-and-reliability-of-mixed-reality-based-performance-tests-in-overweight-and-obese-adults-100641777","NCT07654439","Validity and Reliability of Mixed Reality-Based Performance Tests in Overweight and Obese Adults","Validity and Reliability of the Mixed Reality Adaptation of Performance Tests in Overweight and Obese Individuals","Inclusion Criteria:\n\n* Body Mass Index (BMI) ≥ 25 kg\u002Fm² (overweight or obesity),\n* Ability to ambulate independently,\n* Aged between 18 and 65 years,\n* Willingness to participate voluntarily in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Use of anti-obesity medication,\n* Pregnancy,\n* Latent autoimmune diabetes in adults (LADA),\n* Chronic kidney disease,\n* Active or severe infections,\n* Liver failure,\n* Recent major cardiovascular events,\n* Unstable angina,\n* Heart failure classified as New York Heart Association (NYHA) Class III-IV,\n* Respiratory failure, cardiac arrhythmias, neoplastic diseases, or neurological or musculoskeletal disorders that may limit the safe performance of the tests.","65 Years",{"count":437,"type":22},119,"This study aims to evaluate the validity and reliability of mixed reality (MR)-based adaptations of functional mobility and performance tests developed using the Meta Quest 3 platform by comparing their outcomes with conventional clinical assessments. Virtual and mixed reality technologies have gained increasing attention in clinical measurement due to their potential advantages, including assessment standardization, enhanced user interaction, and automated data collection.\n\nPrevious studies have demonstrated that virtual reality-based performance assessments can provide high reliability and show meaningful associations with traditional clinical measures across different populations. However, visual and vestibular stimuli, depth perception, and changes in movement strategies may cause performance in virtual environments to differ from performance in conventional settings. Therefore, the validity and reliability of each virtual or mixed reality adaptation should be established within the target population.\n\nOverweight and obese individuals exhibit biomechanical and physiological characteristics that may affect balance, gait mechanics, joint loading, and physical performance. Consequently, measurement properties established in other populations cannot be assumed to apply directly to overweight and obese individuals. In addition, factors related to head-mounted displays and motion-tracking systems may influence assessment outcomes.\n\nThe purpose of this study is to evaluate the concurrent validity and test-retest reliability of mixed reality-based performance tests developed using the Meta Quest 3 platform. Measurement error parameters will also be determined to assess the clinical applicability of these MR-based assessments.\n\nThe findings of this study are expected to contribute to the development of safe, standardized, digital, and potentially remote assessment approaches for evaluating functional performance in overweight and obese individuals. Furthermore, the results may strengthen the scientific evidence supporting the use of digital assessment technologies in clinical practice.",[29],[322,219,441,442,443,444,445,446,447],"Mixed Reality","6-Minute Walk Test","Timed Up and Go Test","Five-Repetition Sit-to-Stand Test","Functional Performance","Validity","Reliability",{"date":449,"type":39},"2026-06-17",{"date":451,"type":39},"2026-06-10",{"date":453,"type":22},"2027-05-10",{"name":455,"class":46},"Selcuk University",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":288,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":470,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":47},"100486871","healthy-for-two-home-visiting-h42-hv-health-coaching-for-pregnant-women-100486871","NCT05619705","Healthy for Two-Home Visiting (H42-HV): Health Coaching for Pregnant Women","Effectiveness of Health Coaching to Reduce Cardiometabolic Risk in Early Home Visiting Services","Inclusion Criteria:\n\n* Pregnant, ≤33 weeks gestation\n* Singleton pregnancy\n* Pre pregnancy BMI≥25.0 Kg\u002Fm\\^2 (calculated based on self-reported pre pregnancy height and weight)\n* Able to provide informed consent\n* English or Spanish speaking\n* Completion of screening and baseline data collection\n* Willing to participate in the intervention and data collection procedure (e.g., home weights)\n\nExclusion Criteria:\n\n* Type 1 diabetes or taking insulin prior to delivery\n* Pregnant with multiple fetuses\n* Unable to walk 1 block without pain or shortness of breath\n* Not cleared by the study's clinicians or home visiting program staff\n* Planning to relocate from area during next 1 year\n* Active substance abuse disorder (except marijuana)\n* Psychiatric or substance use related hospitalization in past 1 year\n* Active eating disorder",{"count":464,"type":22},360,[25],"The purpose of this study is to compare the effectiveness of H42-HV integrated into home visiting compared with usual home visiting services in reducing postpartum weight retention (difference between pre-pregnancy weight and weight at 6 months postpartum) among pregnant and postpartum participants. The overall goal is to improve long-term cardiometabolic health.",[371,468,29,469],"Pregnancy Weight Gain","Behavior, Health",[471,472,322,219,473,474],"Behavioral Intervention","Early Childhood Home Visiting","Postpartum","Pregnancy","2026-06-04",{"date":477,"type":39},"2026-06-08",{"date":479,"type":39},"2023-04-25",{"date":481,"type":22},"2026-12-15",{"name":483,"class":46},"Johns Hopkins University",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":288,"minAge":18,"maxAge":104,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":47},"100463576","phase-2-weight-management-plus-lng-iusmegestrol-acetate-in-endometrial-atypical-hyperplasia-100463576","NCT05316493","Weight Management Plus LNG-IUS\u002FMegestrol Acetate in Endometrial Atypical Hyperplasia","Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study","Inclusion Criteria:\n\n1.18 years≤age≤45years 2.BMI (body mass index) ≥24kg\u002Fm2 3.Consent informed and signed 4.Pathologically confirmed as endometrial atypical hyperplasia. Patients with endometrial specimens obtained by endometrial biopsy, diagnostic curettage or hysteroscopy and diagnosed histologically as endometrial atypical hyperplasia. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.\n\n5.Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.\n\n6.Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.\n\nExclusion Criteria:\n\n1. Combined with severe medical disease or liver or kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level elevates to 3 times or more of the upper limit of normal, kidney dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin)\n2. Patients are diagnosed with other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone.\n3. Those who have received high doses of high potency progestin or oral contraceptives within the last 3 months (or those on maintenance medication).\n4. Those who require hysterectomy or other methods other than conservative treatment.\n5. Known or suspected pregnancy.\n6. Those who has contraindications to use progestin.\n7. Deep vein thrombosis, stroke, myocardial infarction.\n8. Severe joint lesions that prevent walking or movement.\n9. untreated or recurrent pelvic inflammatory disease (PID)\n10. an untreated or uncontrolled pelvic infection (vaginal, cervical, uterine);\n11. Cervical dysplasia\n12. Congenital or acquired uterine abnormalities, including uterine fibroid tumors or conditions that affect the shape of the uterus\n13. allergic to the LNG-IUS components\n14. uterine cavity is too large (average uterine diameter is over 7 cm) or have a history of LNG-IUS falling out.\n\nNotes: the last 6 criteria are only applied for patients with LNG-IUS.",{"count":492,"type":22},172,[319,85],"To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.",[496,497,29],"Atypical Endometrial Hyperplasia","Fertility Issues","2026-06-03",{"date":475,"type":39},{"date":501,"type":39},"2022-06-13",{"date":503,"type":22},"2027-02-28",{"name":505,"class":46},"Xiaojun Chen",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":55,"sex":288,"minAge":18,"maxAge":104,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":47},"100424331","pregnancy-exercise-mode-effect-on-childhood-obesity-100424331","NCT04805502","Pregnancy Exercise Mode Effect on Childhood Obesity","Effect of Exercise Modality During Pregnancy on Childhood Obesity Risk","Inclusion Criteria:\n\n* Age: 18 to 40 years old\n* BMI between ≥ 25\n* Pregnancy: Singleton; ≤ 16 weeks gestation\n* Clearance by Obstetric provider for exercise\n\nExclusion Criteria:\n\n* Age: ≤ 17.9 or ≥ 41 years of age\n* BMI \\\u003C25\n* Multi fetal pregnancy\n* Obstetric Provider does not provide clearance for exercise\n* Unable or Unwilling to provide consent\n* Inability to communicate with members of study team, despite use of interpreter\n* Medical Conditions (e,g. HIV\u002FAids, Cancer, Type 1 or 2 Diabetes, Untreated Hypertension, Thyroid Disorders)\n* Use of tobacco products, alcohol, recreational drugs, or medications (oral hypertensive, insulin)\n* Unable to provide phone or email contact",{"count":514,"type":22},300,[25],"The overall objective of this proposal is to conduct a longitudinal prospective study of overweight\u002Fobese (OW\u002FOB) pregnant women and their offspring to determine which prenatal exercise mode will have the greatest impact on maternal and infant cardiometabolic health. This information may lead to clinical practice recommendations that improve childhood health. This randomized controlled trial will recruit 284 OW\u002FOB pregnant women randomized to an exercise intervention (aerobic (AE), resistance (RE), or aerobic+resistance exercise (AERE)) or to no exercise; their infants will be measured at 1, 6, and 12 months of age. This design will test our central hypothesis that AERE and RE training during pregnancy will improve maternal and offspring cardiometabolic outcomes to a greater extent than AE alone. This hypothesis will be tested with two specific aims:\n\nAim 1. Determine the influence of different exercise modes during OW\u002FOB pregnancy on infant cardiometabolic health and growth trajectories. Hypothesis: AE, RE, and AERE by OW\u002FOB pregnant women will improve offspring neuromotor and cardiometabolic measures at 1, 6, and 12 months postpartum (e.g. decreased %body fat, BMI z-score, heart rate \\[HR\\], non-HDL, and C-Reactive Protein (CRP); increased insulin sensitivity) compared to infants of OW\u002FOB pregnant women that do not exercise; AERE and RE will have the greatest impact on improving infant measures.\n\nAim 2. Determine the most effective exercise mode in OW\u002FOB pregnancy on improving maternal cardiometabolic health outcomes. Hypothesis: AE, RE, and AERE by OW\u002FOB pregnant women will improve both maternal cardiometabolic health measures (e.g. decreased BMI z-score, non-HDL, % body fat, HR, weight gain) across pregnancy (16-36 weeks' gestation) and overall pregnancy outcomes (e.g. lower incidence of gestational diabetes, pre-eclampsia, hypertension during gestation) compared to OW\u002FOB pregnant women that do not exercise; AERE and RE will have the greatest impact on improving maternal health measures, with the AERE group having the highest compliance.\n\nThe proposed study will be the first to provide an understanding of the influence of maternal exercise modes on the cardiometabolic health and growth trajectories of offspring who are at increased risk due to maternal OW\u002FOB. This work will have a significant impact on reducing the cycle of OB, potentially providing the earliest and most efficacious intervention to decrease or prevent OB in the next generation.",[474,29],[519],"exercise modes, exercise intervention","2026-06-02",{"date":475,"type":39},{"date":523,"type":39},"2021-10-18",{"date":525,"type":22},"2027-08-30",{"name":527,"class":46},"East Carolina University",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":549},"100580813","phase-1-a-phase-12a-study-of-wve-007-in-adults-living-with-overweight-or-obesity-100580813","NCT06842186","A Phase 1\u002F2a Study of WVE-007 in Adults Living With Overweight or Obesity","A Phase 1\u002F2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity","INLIGHT","Inclusion Criteria: Part A\n\n* Male and female participants aged 18 to 60 years\n* BMI 28 to 35 kg\u002Fm2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg\u002F m2 will be allowed.\n* Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments\n\nInclusion Criteria : Part B\n\n* Male and female participants aged 18 to 60 years\n* BMI 35 to 50 kg\u002Fm2 (inclusive)\n* Thyroid stimulating hormone is within normal range at Screening. May be on supplemental thyroid hormone as managed by their prescribing physician and stable within the last 60 days\n* Have Pre T2D or T2D\n\nExclusion Criteria: Part A\n\n* History or presence of CV disease, including heart failure (New York Heart Association \\[NYHA\\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments\n* History or presence of thyroid disorders\n* Medical history or diagnosis of causes of liver disease\n* Use of any siRNA agent in the prior 12 months\n* Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study\n\nExclusion Criteria: Part B\n\n* History of significant CV disease in the opinion of the Investigator.\n* Use of prescription medications (ie, anti-obesity or psychiatric medications) within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug, except for allowed antihypertensive medications and statins.\n* Taking \\>2 antihypertensive medications, or antihypertensive medication dose was changed in the 60 days prior to Screening.\n* Taking \\>1 cholesterol-lowering medication, or cholesterol-lowering medication dose was changed in the 60 days prior to Screening.\n* Cohorts 1 and 2 (preT2D) only: use of any GLP-1 receptor agonists or dual incretin agonists within the 4 months prior to Screening.\n* Cohorts 4 and 5 (T2D) only: use of insulin or any medication that directly stimulates pancreatic insulin within the 60 days prior to Screening, including sulfonylureas, meglitinides, GLP-1 receptor agonists, dual incretin agonists, and DPP-4 inhibitors.\n* Use of any siRNA agent in the prior 12 months.\n* Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study.",{"count":537,"type":22},296,[192,319],"The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.",[29],"2026-05-29",{"date":520,"type":39},{"date":544,"type":39},"2025-01-31",{"date":546,"type":22},"2027-12",{"name":548,"class":96},"Wave Life Sciences USA, Inc.",6,{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":558,"targetDuration":4,"studyType":393,"phases":4,"briefSummary":560,"conditions":561,"keywords":564,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":4},"100638273","ai-driven-metabolic-cohort-in-overweightobese-chinese-adults-100638273","NCT07584330","AI-Driven Metabolic Cohort in Overweight\u002FObese Chinese Adults","Chinese Overweight\u002FObese - Diabetes Metabolic Spectrum Cohort: An Artificial Intelligence-Driven Prospective Study","COMET-AI","Inclusion Criteria:\n\n1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.\n2. Age between 18 and 60 years (inclusive).\n3. Meets at least one of the following overweight\u002Fobesity criteria: a) BMI ≥ 24 kg\u002Fm²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.\n4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.\n2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \\\u003C 0.1 mIU\u002FL with FT4 \\> upper normal limit; hypothyroidism: TSH \\> 10 mIU\u002FL), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.\n3. Severe liver disease (Child-Pugh class B or C).\n4. Renal insufficiency (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n5. Severe cardiac dysfunction (New York Heart Association class III or IV).\n6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).\n7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%).\n8. Active malignancy (diagnosed or treated within the last 3 years).\n9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).\n10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).\n11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).\n12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes.\n13. Pregnancy or planned pregnancy during the study period.\n14. History of or planned organ transplantation.\n15. Inability to operate the AI-based system or comply with follow-up procedures.\n16. Concurrent participation in another interventional clinical trial that may influence the results of this study.\n17. Unwilling or unable to provide informed consent.",{"count":559,"type":22},2800,"The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight\u002Fobesity to unhealthy overweight\u002Fobesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight\u002Fobesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight\u002Fobesity, metabolically unhealthy overweight\u002Fobesity, and type 2 diabetes with overweight\u002Fobesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.",[29,349,562,563],"Prediabetic State","Metabolic Syndrome",[29,565,563,566,567,568],"Type 2 Diabetes Mellitus","Metabolic Phenotype","Prospective Study","Cohort Study","2026-05-07",{"date":571,"type":39},"2026-05-13",{"date":573,"type":22},"2026-05-01",{"date":575,"type":22},"2032-04-01",{"name":577,"class":46},"Zhujiang Hospital",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":393,"phases":4,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":47},"100626127","prognostic-value-of-sii-and-siri-in-obesity-related-metabolic-complications-100626127","NCT07431593","Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications","Clinical Significance and Prognostic Value of Systemic Immune Inflammation Index and Systemic Inflammation Response Index in Obesity and Associated Metabolic Complications","SIMO-PRO","Inclusion Criteria\n\n* Age ≥ 18 years\n* BMI 25.0-29.9 kg\u002Fm² (overweight) or BMI ≥ 30 kg\u002Fm² (obesity)\n* Ability to attend scheduled clinical visits\n* Willingness to provide informed consent\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding\n* Use of immunosuppressive therapy\n* Active infection\n* Inflammatory disease\n* Malignancy\n* Acute illness affecting immune parameters\n* Conditions interfering with study participation (as assessed by the investigator)\n* Known hematologic disorders affecting leukocyte or platelet counts\n* Chronic inflammatory diseases requiring systemic therapy\n* Recent major surgery (within the last 3 months)\n* Any condition that could confound the relationship between SII\u002FSIRI and obesity-driven inflammation, such as immune disorders",{"count":587,"type":22},200,"This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.",[29,590,563],"Inflammation",[592,593,594,595,596],"obesity","overweight","Systemic Immune Inflammatory Index (SII)","Systemic Inflammation Response Index (SIRI)","inflammation","2026-04-30",{"date":569,"type":39},{"date":600,"type":22},"2026-04",{"date":602,"type":22},"2027-12-31",{"name":604,"class":46},"University of Rijeka",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":615,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":633},"100544589","early-phase-1-abundance-of-a-natural-odour-in-human-cerebrospinal-fluid-after-olfactory-exposure---the-olfo-brain-study-100544589","NCT06370845","ABUNDANCE of A NATURAL ODOUR in HUMAN CEREBROSPINAL FLUID AFTER OLFACTORY EXPOSURE - the OLFO-Brain Study","Abundance of a Natural Odour in Human Cerebrospinal Fluid After Olfactory Exposure - the OLFO-Brain Study","OLFO-Brain","Inclusion Criteria Obese Participants:\n\n* Age 18-60 years\n* Written informed consent\n* Scheduled for routine liquor puncture\n* BMI ≥ 30 kg\u002Fm2\n* No proven diagnose of diabetes\n\nInclusion Criteria Lean Participants:\n\n* Age 18-60 years\n* Written informed consent\n* Scheduled for routine liquor puncture\n* BMI 18-25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Known allergy to the natural odour\n* Acute upper respiratory tract infection, acute or chronic sinusitis\n* Present or past surgical intervention of the nasal cavity, the paranasal sinus, the pituitary or the frontal brain\n* Pregnancy\u002Flactation\n* Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease, severe renal impairment with an estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2)\n* Inability to understand the study procedure and to sign the study consent",{"count":614,"type":22},32,[616],"EARLY_PHASE1","The goal of this clinical trial is to investigate the abundance of a natural odour in human cerebrospinal fluid in obese and lean participants after inhalation thereof. Participants will undergo blood sample collection and inhalation of either a natural odour or placebo through an inhaler in addition to a liquor puncture prescribed in standard of care context.",[29],[620,621,622,623],"natural odour Inhalation","RCT","Placebo Controlled","Cerebrospinal Fluid","2026-04-28",{"date":626,"type":39},"2026-05-04",{"date":628,"type":39},"2026-04-14",{"date":630,"type":22},"2027-10-30",{"name":632,"class":46},"University Hospital, Basel, Switzerland",2,{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":393,"phases":4,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":4},"100634606","weight-loss-goals-and-satisfaction-survey-100634606","NCT07541872","Weight Loss Goals and Satisfaction Survey","An Evaluation of 3D Visualization Tools and Their Effect on Weight Loss Goals and Satisfaction","Inclusion Criteria:\n\n* Adults over 18 years of age\n* BMI ≥ 24.5 kg\u002Fm2\n* currently seeking weight loss\n* Willingness to provide informed consent\n* Willingness to answer all questions related to enrollment criteria and provide the necessary information to render a personalized avatar, including sex, age, race\u002Fethnicity, weight, and height.\n\nExclusion Criteria:\n\n• History of body shape-altering procedures (i.e., breast augmentation, bariatric surgery, amputation)",{"count":642,"type":22},250,"The goal of this observational survey pilot study is to learn how 3D visualization tools (i.e., personalized avatars) influence weight loss goals, satisfaction, confidence, and commitment compared to numerical weight outcomes in weight loss-seeking adults.\n\nThe main questions it aims to answer are:\n\n1. What are contemporary weight loss goals (defined as dream, happy, acceptable, and disappointing weight loss outcomes), and how do they compare to goals reported in prior studies?\n2. Does presenting weight loss outcomes using personalized 3D avatars result in different levels of satisfaction compared to presenting equivalent outcomes numerically as body weight?\n3. Do predictive 3D avatars affect participants' confidence and commitment to achieving weight loss differentially than numerical weight loss goals?\n\nResearchers will compare visual (3D avatar-based) weight loss outcomes to numerical (pounds lost) weight loss outcomes to see if visual presentation lowers satisfaction with potential weight loss and alters confidence and commitment.\n\nParticipants will:\n\n* Complete a one-time online survey\n* Provide demographic and self-reported anthropometric information to generate personalized 3D avatars\n* Report weight loss goals and rate satisfaction with potential weight loss outcomes shown numerically and as 3D avatars.\n* Complete questionnaires assessing psychological and behavioral weight-related factors.",[29],[216,646,647,648,649,650,651],"health behavior","motivation","three-dimensional imaging","digital health","treatment expectations","health communication","2026-04-13",{"date":654,"type":39},"2026-04-21",{"date":656,"type":22},"2026-08",{"date":658,"type":22},"2026-09",{"name":660,"class":46},"Pennington Biomedical Research Center"]